Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 32

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Obesity116Type 2 diabetes mellitus83Overweight51Type 1 diabetes mellitus38Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis22Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Dyslipidaemia8Iron deficiency8Phenylketonuria8+213

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Study on Empagliflozin for Patients with Non-Alcoholic Steatohepatitis (NASH)

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice Praha

Obesity

Not recruiting

Comparing the efficacy and safety of KAI-9531 and semaglutide in people living with obesity who do not have diabetes

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531

Obesity

Not recruiting

Efficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Metsera Inc.

Obesity

Not recruiting

A study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Metsera Inc.

Type 2 diabetes mellitus+3

Not recruiting

A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus+2

Not recruiting

A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus+2

Not recruiting

Study of Orforglipron for Weight Management in People with Obesity or Overweight, With or Without Type 2 Diabetes

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Sponsor:Eli Lilly & Co.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Familial hypertriglyceridaemia+1

Not recruiting

Study of ISIS 678354 for Patients with Severe High Triglycerides

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Isis 678354 Sodium Salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity

Not recruiting

Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim Espana S.A.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide76 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsTirzepatide13 clinical trialsParacetamol12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.